This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, J. Articles by Ravid, K. Search for Related Content PubMed PubMed Citation Articles by Lu, J. Articles by Ravid, K.

An Adenosine Analogue, IB-MECA, Down-Regulates Estrogen Receptor and Suppresses Human Breast Cancer Cell Proliferation¹

Department of Biochemistry and Cancer Center, Boston University School of Medicine, Boston, Massachusetts 02118

Adenosine, a natural metabolite, plays important roles in several physiological and pathological processes, including modulation of cellular proliferation. Here, we report that among different adenosine analogues tested, micromolar concentrations of the A₃ adenosine receptor (A₃AR)-selective agonist N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) completely inhibited the growth of the human breast cancer cell lines MCF-7 and ZR-75 while inducing apoptosis in T47D and Hs578T cells, which do not express A₃AR mRNA. In MCF-7 cells, A₃AR overexpression did not increase the sensitivity to drug treatment and an A₃AR antagonist did not abolish IB-MECA effect. In search for mechanisms of the effect of this ligand, we found that in estrogen receptor (ER)-positive cells, IB-MECA rapidly down-regulated ER at mRNA and protein levels and consequently at the transcriptional activity level. Moreover, overexpression of ER in MCF-7 cells alleviated the proliferation inhibition induced by IB-MECA. The inhibitory effects on cell growth and to some extent on ER were mimicked by 2-chloro-adenosine >3'-deoxyadenosine> adenosine but not by a variety of other ligands. Our studies indicate that IB-MECA can down-regulate ER and inhibit proliferation or induce apoptosis in different breast cancer cell types and raise the possibility of using this and related compounds in breast cancer treatment.

This article has been cited by other articles:

				K. Ishitani, J. Lin, J. E. Manson, J. E. Buring, and S. M. Zhang Caffeine Consumption and the Risk of Breast Cancer in a Large Prospective Cohort of Women Arch Intern Med, October 13, 2008; 168(18): 2022 - 2031. [Abstract] [Full Text] [PDF]

				H. Amlal, S. Faroqui, A. Balasubramaniam, and S. Sheriff Estrogen Up-regulates Neuropeptide Y Y1 Receptor Expression in a Human Breast Cancer Cell Line. Cancer Res., April 1, 2006; 66(7): 3706 - 3714. [Abstract] [Full Text] [PDF]

				H. Chung, J.-Y. Jung, S.-D. Cho, K.-A Hong, H.-J. Kim, D.-H. Shin, H. Kim, H. O. Kim, D. H. Shin, H. W. Lee, et al. The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor-positive and estrogen receptor-negative human breast cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 685 - 692. [Abstract] [Full Text] [PDF]

				H. G. Nguyen, D. Chinnappan, T. Urano, and K. Ravid Mechanism of Aurora-B Degradation and Its Dependency on Intact KEN and A-Boxes: Identification of an Aneuploidy-Promoting Property Mol. Cell. Biol., June 15, 2005; 25(12): 4977 - 4992. [Abstract] [Full Text] [PDF]